Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

doi:10.1007/s12185-025-04100-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

International journal of hematology - 1 Mar 2026

Iriyama Noriyoshi, Nakayama Hitomi, Nakagawa Masaru, Takahata Atsushi, Sato Eriko, Takano Motoki, Okada Keigo, Toyama Kohtaro, Hayashi Toshiaki, Abe Takashi, Tanaka Keisuke, Senpuku Yasuhiko, Osada Yuki, Watanabe Junichi, Yamamoto Koh, Sekiguchi Yasunobu, Oshikawa Gaku, Kimura Yuta, Tokuhira Michihide, Suzuki Ken, Kumagai Takashi, Ikezoe Takayuki, Toyota Shigeo, Miura Katsuhiro, Nakazato Tomonori, Mori Takehiko

Abstract excerpt

AIM AND PURPOSE: This study aimed to investigate the relationship between myeloma cell maturity, clinical profiles, and treatment outcomes in patients with multiple myeloma (MM). PATIENTS AND METHODS: The J-CHARGE-MM database includes data from 1200 MM patients diagnosed between January 2011 and January 2023. Immunophenotyping by flow cytometry using antibodies against CD38, CD49e, and MPC-1 was used to evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bortezomib

Share to Immunophenotyping

Share to Lenalidomide

Share to Multiple Myeloma

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 41206814
DOI: 10.1007/s12185-025-04100-2

Genes

CD38

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.PMID 41206814Read ↗

SnapShot: Multiple Myeloma.Semantic proximity Read ↗

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaSemantic proximity Read ↗

Challenges, Difficulties, and Delayed Diagnosis of Multiple MyelomaSemantic proximity Read ↗

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patientsSemantic proximity Read ↗

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.Semantic proximity Read ↗

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity Read ↗

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myelomaSemantic proximity Read ↗

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read ↗

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.Semantic proximity Read ↗

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseSemantic proximity Read ↗

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.